Skip to main content
Premium Trial:

Request an Annual Quote

Genomenon, Nostos Genomics to Integrate Technologies to Improve Rare Disease Dx

NEW YORK – Genomenon said Tuesday that it has partnered with German bioinformatics startup Nostos Genomics to integrate its Mastermind genomic search engine into the Nostos AIon AI-driven variant interpretation platform.

According to Ann Arbor, Michigan-based Genomenon, this integration will allow AIon users to preview lists of published articles related to their searches from within the AIon interface. This, the companies said, will help improve diagnosis of rare genetic diseases.

Mastermind allows clinicians to index genomic variants from scientific publications to help diagnose patients suffering from rare and genetic diseases. Genomenon offers a freemium model that it said makes the engine freely available to a broad range of scientists, academics, and clinicians.

Nostos Genomics, which is headquartered in Berlin, combines artificial intelligence and functional genomics in its AIon product. 

"This collaboration stemmed from a shared desire to not only provide clinicians with the best decision support possible, but also improve the accuracy, speed, and accessibility of genetic testing to lessen the burden of the diagnostic odyssey for patients," Nostos CEO David Gorgan said in a statement.

"Our relationship extends Mastermind's global reach, and connecting Mastermind with AIon provides significant value in cutting turnaround time and increasing diagnostic yield for genetic testing labs," added Genomenon CEO Mike Klein.

Genomenon had signed an agreement with BC Platforms in February to integrate the Mastermind engine into BC's products for rare disease diagnostics research. The firm also raised $5.3 million in a round of venture capital that closed in March.